- cafead   Nov 14, 2024 at 10:42: PM
via In an unusual reversal, key drug regulators in Europe are now saying Leqembi, a high-profile medicine for Alzheimer’s disease, should be approved there, though only for patients less likely to experience a certain kind of concerning side effect.
article source
article source